OR WAIT null SECS
September 05, 2024
Article
The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.
August 22, 2024
Video
Strnad explains how although moderate alcohol consumption is likely tolerable in most individuals with AATD, careful monitoring of liver-related parameters is still important.
August 17, 2024
Moderate alcohol consumption did not significantly impact liver-related parameters in patients with the Pi*MZ and Pi*ZZ genotypes of alpha-1 antitrypsin deficiency.
August 16, 2024
Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.
August 05, 2024
Strnad explains how findings from the SEQUOIA study inform fazirsiran’s use in patients with AATD-associated liver disease and its further evaluation in future phase 3 trials.
July 30, 2024
Greater circulating Z-polymer levels were associated with an increased risk of adverse clinical outcomes in adults with AATD and the PiZZ genotype.
July 24, 2024
The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.
July 10, 2024
Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.
July 08, 2024
Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.
June 21, 2024
Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.
